The valuations available on China's booming Star Market are prompting US dollar managers to consider restructuring companies for onshore listings. How long will the fervor last?
What possesses a Chinese company – and its investors, if they get a say – to go to the trouble of dismantling an offshore structure with a view to pursuing an onshore IPO? Money, obviously. And right...
Hangzhou-based drug developer Sumgen Biotech has raised RMB220 million ($32 million) in a Series B funding led by Addor Capital.
Increased climate change awareness on a corporate level is leading to more investment – either direct or through funds – in start-ups that offer mitigation solutions. Asia is a key geography
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Kyee Technology, a Chinese digital medical platform has raised RMB430 million ($64 million) in a Series D round led by Tencent Holdings. Other investors include Longmen Capital, Dyee Capital and Royal Sea Capital.